Guía de práctica clínica: tratamiento agudo de las enfermedades inflamatorio-desmielinizantes del sistema nervioso central: esclerosis múltiple, espectro de la neuromielitis óptica, encefalomielitis diseminada aguda, enfermedades asociadas a anticuerpos antiglicoproteína de la membrana del oligodendrocito, mielitis aguda y neuritis óptica. Elaborada por el Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina

Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, 17, 162, 10.1016/S1474-4422(17)30470-2 Miller, 2008, Differential diagnosis of suspected multiple sclerosis: a consensus approach, Mult Scler, 14, 1157, 10.1177/1352458508096878 Barboza, 2010, Propuesta para la unificación de criterios metodológicos en la elaboración de guías de práctica clínica de la Sociedad Neurológica Argentina, Neurol Arg., 35 Balshem, 2011, GRADE guidelines: 3 Rating the quality of evidence, J Clin Epidemiol., 64, 401, 10.1016/j.jclinepi.2010.07.015 Barboza, 2022, Guía de práctica clínica: tratamiento sintomático de esclerosis múltiple. Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina, Neurol Arg, 14, 108 Brouwers, 2010, AGREE II: Advancing guideline development, reporting and evaluation in health care, CMAJ., E839, 10.1503/cmaj.090449 Nos, 2004, Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis, Mult Scler, 10, 413, 10.1191/1352458504ms1068oa Ramo-Tello, 2014, A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS, Mult Scler., 20, 717, 10.1177/1352458513508835 Citterio, 2000, Corticosteroids or ACTH for acute exacerbations in multiple sclerosis, Cochrane Database of Syst Rev Barnes, 1985, Intravenous methylprednisolone for multiple sclerosis in relapse, J Neurol Neurosurg Psychiatry, 48, 157, 10.1136/jnnp.48.2.157 Milanese, 1989, Double-Blind Randomized Trial of ACTH versus Dexamethasone versus Methylprednisolone in Multiple Sclerosis Bouts, Eur Neurol, 29, 10, 10.1159/000116368 Thompsom, 1989, Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS, Neurology, 39, 969, 10.1212/WNL.39.7.969 Milligan, 1987, A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects, J Neurol Neurosurg Psychiatry, 50, 511, 10.1136/jnnp.50.5.511 Durelli, 1986, High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations, Neurology, 36, 238, 10.1212/WNL.36.2.238 Filipovic, 1997, The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis, J Neurol Sci, 152, 147, 10.1016/S0022-510X(97)00159-7 Beck, 1992, A Rondomized, controlled trial of corticosteroids in the treatment of acute optic neuritis, N Engl J Med., 326, 581, 10.1056/NEJM199202273260901 Sellebjerg, 2005, EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses, Eur J Neurol., 12, 939, 10.1111/j.1468-1331.2005.01352.x Lyons, 1988, Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects, J Neurol Neurosurg Psychiatry, 51, 285, 10.1136/jnnp.51.2.285 Alam, 1993, Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose, J Neurol Neurosurg Psychiatry., 56, 1219, 10.1136/jnnp.56.11.1219 Sellebjerg, 1999, Randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis, Neurology, 52, 1479, 10.1212/WNL.52.7.1479 Burton, 2012, Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, Cochrane Database of Syst Rev Le Page, 2015, Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial, Lancet, 386, 974, 10.1016/S0140-6736(15)61137-0 Morrow, 2018, Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids A Randomized Clinical Trial, JAMA Neurol., 75, 690, 10.1001/jamaneurol.2018.0024 Barnes, 1997, Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis, Lancet, 349, 902, 10.1016/S0140-6736(96)06453-7 Martinelli, 2009, A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS, Neurology., 73, 1842, 10.1212/WNL.0b013e3181c3fd5b Morrow, 2012, Kremenchutzky m, MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses, Can J Neurol Sci., 39, 352, 10.1017/S0317167100013500 Luetic, 2021, Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting, Mult Scler Relat Disord., 54, 103148, 10.1016/j.msard.2021.103148 Perumal, 2008, Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis, Eur J Neurol, 15, 677, 10.1111/j.1468-1331.2008.02146.x Stoppe, 2017, Outcome of MS relapses in the era of disease-modifying therapy, BMC Neurology, 17, 151, 10.1186/s12883-017-0927-x Oliveri, 1998, Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study, Neurology, 50, 1833, 10.1212/WNL.50.6.1833 Fierro, 2002, A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis, Acta Neurol Scand., 105, 152, 10.1034/j.1600-0404.2002.1o369.x Pfeuer, 2020, Comparing Plasma Exchange to Escalated MethylPrednisolone in Refractory Multiple Sclerosis Relapses, J. Clin. Med., 9, 35, 10.3390/jcm9010035 Weinshenker, 1999, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Ann Neurol, 46, 878, 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q Weiner, 1989, Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis, Neurology, 39, 1143, 10.1212/WNL.39.9.1143 Blechinger, 2021, Therapeutic plasma exchange in steroid refractory multiple sclerosis relapses. A retrospective two-center study, Ther Adv Neurol Disord, 14, 1, 10.1177/1756286420975642 Skorupka, 2019, Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis:A Retrospective Monocentric Analysis, Transfus Med Hemother, 46, 417, 10.1159/000504027 Correia, 2018, Plasma exchange in severe acute relapses of multiple sclerosis – Results from a Portuguese cohort, Mult Scler Relat Disord, 19, 148, 10.1016/j.msard.2017.12.001 Ehler, 2015, Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients, PLoS One., 10, 10.1371/journal.pone.0134583 Magaña, 2011, Beneficial Plasma Exchange Response in CNS Inflammatory Demyelination, Arch Neurol., 68, 870, 10.1001/archneurol.2011.34 Habek, 2010, Treatment of Steroid Unresponsive Relapse With Plasma Exchange in Aggressive Multiple Sclerosis, Ther Apher Dial., 14, 298, 10.1111/j.1744-9987.2009.00794.x Trebst, 2009, Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis, Blood Purif., 28, 108, 10.1159/000224630 Marrodan, 2021, Therapeutic plasma exchange in MS refractory relapses: Long-term outcome, Mult Scler Relat Disord, 55, 103168, 10.1016/j.msard.2021.103168 Padmanabhan, 2019, Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue, J Clin Apher, 34, 171, 10.1002/jca.21705 -Shemin, 2007, Complications of Therapeutic Plasma Exchange:A Prospective Study of 1,727 Procedures, J Clin Apher, 22, 270, 10.1002/jca.20143 Lipphardt, 2020, Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis, J Clin Med, 9, 1597, 10.3390/jcm9051597 Faissner, 2016, Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses, J Neurol, 263, 1092, 10.1007/s00415-016-8105-4 Dorst, 2019, Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial, E Clinical Medicine, 16, 98 Elovaara, 2011, Intravenous Immunoglobulins Are a Therapeutic Option in the Treatment of Multiple Sclerosis Relapse, Clin Neuropharmacol, 34, 84, 10.1097/WNF.0b013e31820a17f3 Sorensen, 2004, Neurology, 63, 2028, 10.1212/01.WNL.0000145798.61383.39 Visser, 2004, A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS, Mult Scler., 10, 89, 10.1191/1352458504ms978sr Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology., 85, 177, 10.1212/WNL.0000000000001729 Kawachi, 2017, Neurodegeneration in multiple sclerosis and neuromyelitis optica, J Neurol Neurosurg Psychiatry, 88, 137, 10.1136/jnnp-2016-313300 Beck, 2008, Treatment of Acute Optic Neuritis A Summary of Findings From the Optic Neuritis Treatment Trial, Arch Ophthalmol, 126, 994, 10.1001/archopht.126.7.994 Kleiter, 2016, Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses, Ann Neurol., 79, 206, 10.1002/ana.24554 Demuth, 2022, Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study, J Neuroinflammation., 19, 62, 10.1186/s12974-022-02420-2 Contentti, 2021, Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina, Mult Scler J Exp Transl Clin., 7 Stiebel-Kalish, 2019, Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?, Neurol Neuroimmunol Neuroinflamm., 6, e572, 10.1212/NXI.0000000000000572 Yamasaki, 2016, Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica, Mult Scler., 22, 1337, 10.1177/1352458515617248 Songthammawat, 2020, Clinical trial A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous IVMP and PLEX, Mult Scler Relat Disord., 38, 101506, 10.1016/j.msard.2019.101506 Song, 2019, Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders, Int Ophthalmol., 39, 2477, 10.1007/s10792-019-01090-z Carnero Contentti, 2020, Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice, Mult Scler Relat Disord., 45, 102428, 10.1016/j.msard.2020.102428 Kleiter, 2018, Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions, Neurol Neuroimmunol Neuroinflamm., 5, e504, 10.1212/NXI.0000000000000504 Bonnan, 2018, Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders, J Neurol Neurosurg Psychiatry., 89, 346, 10.1136/jnnp-2017-316286 Srisupa-Olan, 2018, Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders, Mult Scler Relat Disord., 20, 115, 10.1016/j.msard.2018.01.010 Abboud, 2016, Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange, Mult Scler., 22, 185, 10.1177/1352458515581438 Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012;126:103-8. DOI: 10.1111/j.1600-0404.2011.01612.x. Bonnan, 2009, Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder, Mult Scler., 15, 487, 10.1177/1352458508100837 Merle, 2012, Treatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica, Arch Ophthalmol., 130, 858, 10.1001/archophthalmol.2012.1126 Jiao, 2018, Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-Term Outcome, Clin Ther., 40, 603, 10.1016/j.clinthera.2018.03.007 Lim, 2013, Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders, Mult Scler., 19, 1216, 10.1177/1352458512471875 Elsone, 2014, Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients, Mult Scler., 20, 501, 10.1177/1352458513495938 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J Neuroinflammation., 13, 280, 10.1186/s12974-016-0718-0 Ramanathan, 2018, Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J Neurol Neurosurg Psychiatry., 89, 127, 10.1136/jnnp-2017-316880 Jurynczyk, 2017, Clinical presentation and prognosis in MOG-antibody disease: a UK study, Brain., 140, 3128, 10.1093/brain/awx276 Hacohen, 2018, Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, JAMA Neurol., 75, 478, 10.1001/jamaneurol.2017.4601 Bruijstens, 2020, E.U. paediatric MOG consortium consensus: Part 5 e Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders, Eur J Paediatr Neurol., 29, 41, 10.1016/j.ejpn.2020.10.005 Savransky, 2019, Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination, Neurology., 93, e2065, 10.1212/WNL.0000000000008551 Ballow, 2007, Safety of IGIV therapy and infusion-related adverse Events, Immunol Res., 38, 122, 10.1007/s12026-007-0003-5 Krupp, 2013, Mult Scler, 19, 1261, 10.1177/1352458513484547 Tenembaum, 2002, Acute disseminated encephalomyelitis. A long-term follow-up study of 84 pediatric patients, Neurology., 59, 1224, 10.1212/WNL.59.8.1224 Li, 2022, Clinical Presentation and Outcomes of Acute Disseminated Encephalomyelitis in Adults Worldwide: Systematic Review and Meta-Analysis, Front Immunol, 13, 870867, 10.3389/fimmu.2022.870867 López-Chiriboga, 2018, Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders, JAMA Neurol., 75, 1355, 10.1001/jamaneurol.2018.1814 Anlar, 2003, Acute Disseminated Encephalomyelitis in Childres Outcome and Prognosis, Neuropediatrics., 34, 194, 10.1055/s-2003-42208 RamachandranNair, 2005, Plasmapheresis in Childhood Acute Disseminated Encephalomyelitis, Indian Pediatr., 42, 479 Elovaara, 2008, EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases, Eur J Neurol., 15, 893, 10.1111/j.1468-1331.2008.02246.x Bennett, 2019, Optic Neuritis, Continuum (Minneap Minn), 25, 1236 Petzold, 2022, Diagnosis and classification of optic neuritis, Lancet Neurol., 21, 1120, 10.1016/S1474-4422(22)00200-9 Gal, 2015, Corticosteroids for treating optic neuritis, Cochrane Database Syst Rev. Osinga, 2017, Time is vision in recurrent optic neuritis, Brain Res., 1673, 95, 10.1016/j.brainres.2017.08.012 Deschamps, 2016, Plasma exchange response in 34 patients with severe optic neuritis, J Neurol., 263, 883, 10.1007/s00415-016-8073-8 Koziolek, 2012, Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis, J Neuroinflammation., 9, 80, 10.1186/1742-2094-9-80 Noseworthy, 2001, A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis, Neurology., 56, 1514, 10.1212/WNL.56.11.1514 Roed, 2005, A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis, Neurology, 64, 804, 10.1212/01.WNL.0000152873.82631.B3 Transverse Myelitis Consortium Working Group* Proposed diagnostic criteria and nosology of acute transverse myelitis Neurology. 2002;59(4):499-505. doi: 10.1212/wnl.59.4.499. Greenberg, 2007, Idiopathic transverse myelitis Corticosteroids, plasma exchange, or cyclophosphamide, Neurology., 68, 1614, 10.1212/01.wnl.0000260970.63493.c8 Scott, 2011, Neurology., 77, 2128, 10.1212/WNL.0b013e31823dc535 Wang, 2022, Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus, Ther Adv Chronic Dis, 13, 10.1177/20406223221097330 Chiganer, 2021, Transverse Myelitis in Systemic Lupus Erythematosus: Clinical Features and Prognostic Factors in a Large Cohort of Latin American Patients, J Clin Rheumatol., 27, S204, 10.1097/RHU.0000000000001322